Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple MyelomaSagar Lonial, Shaji Kumar, Ralph V. Boccia et al.|Blood|2021Cited by 3